Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,346.20 +208.13 1.37%
Hang Seng 23,469.60 +386.93 1.68%
S&P/ASX 200 5,206.20 +25.43 0.49%
  • Exchange: NASDAQ CM
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

GNVC:US

0.6600 USD 0.0301 4.36%

As of 20:10:00 ET on 05/17/2013.

Company Profile for GenVec Inc (GNVC)

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. The Company specializes in the treatment of cancers, including pancreatic cancer, esophageal cancer, rectal caner, and head and neck cancer. The Company is also involved in studies involving hearing loss and balance disorders. GenVec also develops vaccines for infectious diseases.

Contact Information

GenVec Inc

65 West Watkins Mill Road
Gaithersburg, MD 20878
United States
Phone: 1-240-632-0740
Fax: 1-240-632-0735

Key Executives for GenVec Inc (GNVC)

Cynthia L CollinsPresident/CEODouglas J SwirskySenior VP/CFO/Treasurer/Secy
Bryan T ButmanSenior VP:Vector OperationsDouglas E BroughVP:Research
Michael C TuckerVP:Legal Affairs & Strategy

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil